Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GDC-6988 in Patients With Muco-obstructive Disease
NCT06603246Phase 1Terminated
- Sponsor
- Genentech
- Start
- Nov 2024
- Primary completion
- Aug 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of GDC-6988 in Non-cystic fibrosis bronchiectasis (NCFB) and chronic obstructive pulmonary disease (COPD), sponsored by Genentech. Primary endpoints: Percentage of Participants With Adverse Events up to 6 weeks and Percentage of Participants With Spirometry Abnormalities up to 6 weeks. Started Nov 2024; status: terminated.
02
Drugs
GDC-6988
03
Conditions
Non-cystic fibrosis bronchiectasis (NCFB)chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on NCT06603246.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06603246.